Document is current
Any future updates will be listed below
-
Authors
Baldi, Samantha https://orcid.org/0000-0002-3384-247X
Chiulli, Nicole
Palm, Stephan
Frandsen, Summer
Pell, Gaby S.
Zibman, Samuel
Rodriguez-Ponde, Josias
Brown, Joshua C. https://orcid.org/0000-0003-0887-2746
Siddiqi, Shan H. https://orcid.org/0000-0002-0967-9289
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21MH126271)
- License Information
-
More Information
Article History
Received: 28 April 2025
Revised: 12 June 2025
Accepted: 12 June 2025
First Online: 30 June 2025
Competing interests
: GP and SZ are employed by and have a financial interest in BrainsWay. JCB receives financial support as an editorial stipend from Elsevier. JCB effort is supported by the Brain & Behavior Research Foundation Young Investigator Grant, (#31748), the Cindy & Paul Gamble Fund, the Marlene Zuckerman Fund, the McLean Hospital Center of Excellence in Depression and Anxiety Disorders, and the Department of Defense Advanced Research Projects Agency (HR00112320037). The views, opinions and/or findings expressed are those of the author and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. SHS serves as a consultant for Kaizen Brain Center, Acacia Mental Health, and Magnus Medical. SHS owns stock in BrainsWay Inc (publicly traded) and Magnus Medical (not publicly traded). SHS owns independent intellectual property on the use of brain network mapping to target neuromodulation. SHS effort is supported by the NIH (grant nos. K23MH121657 and R21MH126271), the Brain and Behavior Research Foundation Young Investigator Grant, the Baszucki Brain Research Fund and the Department of Veterans Affairs (grant no. I01CX002293). The remaining authors declare no competing interests.
